ft 31 mar 94 technolog deadli challeng prove costli daniel green examin continu search effect sepsi treatment seri drug sepsi kill 200 000 peopl year europ north america almost lethal least three larg us biotechnolog compani tri develop drug treat sepsi liter mean infect drug promis much earli develop eventu fail fulfil promis cost million dollar demand sepsi treatment nevertheless remain strong sepsi victim spend week intens care cost exceed pound 2 000 day clear cure yet financi reward compani develop success sepsi drug enorm medic challeng larg condit complex sepsi difficult even defin doctor various describ bacteri infect blood acut low blood pressur sometim call septic toxic shock bodi wide inflamm vital organ three correct way sepsi drug one tri deal kind overwhelm infect send peopl intens care ward problem infect bodi respons infect spread bodi releas score chemic call cytokin tri fight effect includ rapid fall blood pressur lead shock inflamm mani part bodi system inflamm combin infect poison exud bacteria low blood pressur system inflamm lead failur vital organ eventu death one doctor work health regulatori bodi say bodi simpli overwhelm even heavi dose antibiot work half sepsi suffer die within 28 day diagnosi infect shock inflamm affect human bodi varieti biochem mechan call cascad precis mechan yet clear may 100 cytokin involv mean even drug succe block part cascad step could bypass shock system inflamm aris anoth rout accord intens care specialist dr david bennett st georg hospit toot london enough sepsi victim rang young person car accid mother childbirth pension suffer chronic diseas diabet cancer surprisingli patient react differ sepsi drug receiv typic larg hospit may one sepsi victim week conduct statist signific clinic trial difficult uncertainti mechan sepsi test potenti treatment drug compani follow score differ approach control condit three us biotechnolog compani far fail demonstr effect drug illustr two approach centocor xoma develop anti endotoxin drug block poison produc bacteria last year centocor stop clinic trial drug centoxin data show patient placebo live longer drug compani huge sale market team built centoxin launch lost job six month earlier us food drug administr decid trial xoma e 5 drug prove efficaci third case synergen evid ambigu drug antril design block effect interleukin 1 chemic involv earli stage onset sepsi year ago compani chief execut left antril appar failur clinic trial three compani combin peak market capitalis dollar 4 5bn pound 3 1bn two year ago figur less pound 1bn analysi antril trial publish two month ago show may effect especi sick patient say bill sibbald professor medicin head critic care programm victoria hospit london ontario canada sibbald acknowledg nevertheless need data clinic trial strong evid whether antril work appli greater extent drug yet face full rigour larg clinic trial one popular altern tackl interleukin 1 block action anoth protein tumour necrosi factor tnf involv earli sepsi compani follow rout includ celltech one biggest uk biotechnolog compani bayer german pharmaceut group chiron one largest us biotechnolog compani centocor anoth drug howev method may solv problem sepsi either least one set clinic trial anti tnf drug stop recent month appear benefit patient tnf may right place cascad right target say deputi chairman one biotechnolog compani british biotechnolog announc plan week rais pound 93m sharehold drug call lexipaf act platelet activ factor paf yet anoth part cascad paf activ bodi defens white cell produc encourag white cell attack healthi tissu paf combat agent also mix fortun trial number establish drug compani side atlant thought abandon cut back paf research anoth rout follow cortech us compani compound call bradycor interfer action bradykinin part inflammatori cascad compani uk wellcom tackl nitric oxid corros chemic produc sepsi lower blood pressur chemic bind bacteri poison cell attach bodi defens white blood cell otherwis healthi tissu wellcom announc yesterday licenc nitric oxid fight chemic fujisawa usa hope start clinic trial later year yet approach follow compani small biotechnolog busi like california gilead drug industri giant eli lilli us japan eisai sepsi exampl high risk high reward therapeut area healthcar combin virtual guarante shortag compani tri find solut one thing independ observ agre effect drug identifi short term much luck scienc sibbald conced clinic trial also test theori sepsi work one yet know precis part cascad crucial difficulti conduct statist meaning clinic trial remain bennett say perhap 5 000 patient subject trial compar ten even hundr thousand normal demand govern regul healthcar sector indirectli acknowledg drug compani robert thompson synergen vice presid research clinic affair say right treatment complex condit may combin drug still room optim howev five year therapi modul inflammatori respons syndrom benefici way say sibbald say move cure prevent next month treatment multipl sclerosi articl last six month look pharmaceut advanc follow area prostat 25 februari wound heal 21 januari obes 23 decemb contracept 12 novemb anaesthet 15 octob diabet 17 septemb